Heinrich Wieland Prize: Closing in on the cause of diabetes

Boehringer IngelheimFor his milestone discoveries on the development of diabetes, Prof. Markus Stoffel from the Institute of Molecular Systems Biology at the ETH Zurich was awarded the Heinrich Wieland Prize, one of the most treasured science awards in Germany. He received the distinction with EUR 50,000 prize money for his work in deciphering important mechanisms of blood sugar regulation and lipid metabolism in the body.

During the award ceremony at the Ludwig-Maximillians-Universität in Munich, the renowned internist with a research focus on nutrition Prof. Nepomuk Zöllner was honored, as well, with the Heinrich Wieland "Medal in Gold" for his lifetime achievement in gout research.

Professor Stoffel (46), tenured since 2006 at the ETH Zürich, discovered two fundamental biochemical signaling pathways in cells. When these break down, type 2 diabetes, which affects 90 percent of all patients with diabetes, can develop. In people with type 2 diabetes, an insulin sensor in the liver malfunctions, thus preventing the organ from reacting properly to the blood sugar reducing hormone insulin. Prof. Stoffel also showed that so-called microRNAs control cholesterol production in the liver and insulin secretion in the pancreas. As such, they could also play a role in diabetes. The metabolism expert is convinced that, "in the future, insulin sensors and microRNAs might provide points of attack for novel drugs in treating type 2 diabetes."

"Even though we have good treatments for diabetes today, there is still much to learn about the molecular causes and mechanisms of this widespread condition," remarked Professor Konrad Sandhoff, Chairman of the Board of Trustees in recognition of the laureate's achievements. However, the medical researcher's work still falls in the realm of basic research, making quick breakthroughs in therapeutic applications unlikely.

"We are awarding the Heinrich Wieland Prize in appreciation of the fruits borne by basic research in recent years, especially in the field of diabetes," declared Dr Andreas Barner, Vice Chairman of the Board of Managing Directors and Head of Research, Development and Medicine at Boehringer Ingelheim. "This is the kind of basic research that is going to drive the development of tomorrow's medicine. Professor Stoffel's findings are even more significant in light of the growing numbers of diabetic patients worldwide, expected to reach 366 million by 2030."

The Heinrich Wieland Prize has been awarded annually since 1964 in honor of the German chemist, lipid researcher and Nobel Prize winner Prof. Heinrich Otto Wieland (1877 to 1957). Professor Wieland was associated with Boehringer Ingelheim and founded the company's first scientific research department. The Heinrich Wieland Prize distinguishes exceptional scientific work in metabolism research. An independent Board of Trustees selects the prizewinner.

The Heinrich Wieland Medal in Gold is awarded in recognition of the lifetime achievement of an outstanding scientist. Professor Nepomuk Zöllner is only the fourth laureate of this prize, which was bestowed on him in recognition of his work as one of the most productive gout researchers. The 85-year old worked for 30 years at the Ludwig-Maximilians-Universität in Munich and, as a result of his exceptional clinical and experimental research work, is one of the most highly regarded experts in his field.

Prof Nepomuk Zöllner was Chairman of the Board of Trustrees of the Heinrich Wieland Prize from 1996 until 2006 and was succeeded by Prof Konrad Sandhoff in 2006.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...